Evaluation Table

Lohia et al. Respir Res (2021) 22:37
https://doi.org/10.1186/s12931-021-01647-6

R E S E A R C H

Preexisting respiratory diseases and clinical
outcomes in COVID-19: a multihospital cohort
study on predominantly African American
population
Prateek Lohia1* , Kalyan Sreeram1, Paul Nguyen1, Anita Choudhary1, Suman Khicher1, Hossein Yarandi2,
Shweta Kapur2 and M. Safwan Badr1

Abstract
Background: Comorbidities play a key role in severe disease outcomes in COVID-19 patients. However, the literature
on preexisting respiratory diseases and COVID-19, accounting for other possible confounders, is limited. The primary
objective of this study was to determine the association between preexisting respiratory diseases and severe disease
outcomes among COVID-19 patients. Secondary aim was to investigate any correlation between smoking and clinical
outcomes in COVID-19 patients.

Methods: This is a multihospital retrospective cohort study on 1871 adult patients between March 10, 2020, and
June 30, 2020, with laboratory confirmed COVID-19 diagnosis. The main outcomes of the study were severe disease
outcomes i.e. mortality, need for mechanical ventilation, and intensive care unit (ICU) admission. During statistical
analysis, possible confounders such as age, sex, race, BMI, and comorbidities including, hypertension, coronary artery
disease, congestive heart failure, diabetes, any history of cancer and prior liver disease, chronic kidney disease, end-
stage renal disease on dialysis, hyperlipidemia and history of prior stroke, were accounted for.

Results: A total of 1871 patients (mean (SD) age, 64.11 (16) years; 965(51.6%) males; 1494 (79.9%) African Americans;
809 (43.2%) with ≥ 3 comorbidities) were included in the study. During their stay at the hospital, 613 patients (32.8%)
died, 489 (26.1%) needed mechanical ventilation, and 592 (31.6%) required ICU admission. In fully adjusted models,
patients with preexisting respiratory diseases had significantly higher mortality (adjusted Odds ratio (aOR), 1.36; 95%
CI, 1.08–1.72; p = 0.01), higher rate of ICU admission (aOR, 1.34; 95% CI, 1.07–1.68; p = 0.009) and increased need for
mechanical ventilation (aOR, 1.36; 95% CI, 1.07–1.72; p = 0.01). Additionally, patients with a history of smoking had
significantly higher need for ICU admission (aOR, 1.25; 95% CI, 1.01–1.55; p = 0.03) in fully adjusted models.
Conclusion: Preexisting respiratory diseases are an important predictor for mortality and severe disease outcomes,
in COVID-19 patients. These results can help facilitate efficient resource allocation for critical care services.

Keywords: COVID-19, Mechanical ventilation, Intensive care, Smoking, tobacco, Mortality

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction
Coronavirus disease-2019 (COVID-19) has infected
close to 55.6 million people worldwide and resulted
in more than 1.34 million deaths as of late-Novem-
ber 2020. In the United States (US) alone, more than
11.6 million people have been infected and 250,000

Open Access

*Correspondence: [email protected]
1 Department of Internal Medicine, Wayne State University, 4201 St
Antoine, Detroit, MI UHC 5C, USA
Full list of author information is available at the end of the article

http://orcid.org/0000-0003-4148-9597

http://creativecommons.org/licenses/by/4.0/

http://creativecommons.org/publicdomain/zero/1.0/

http://creativecommons.org/publicdomain/zero/1.0/

http://crossmark.crossref.org/dialog/?doi=10.1186/s12931-021-01647-6&domain=pdf

Page 2 of 9Lohia et al. Respir Res (2021) 22:37

people have died. Early reports from the US sug-
gest that patients with preexisting comorbid diseases
including chronic lung diseases are at a higher risk of
severe COVID-19 disease [1–3]. Similar studies from
China [4–7] and Italy [8] have noted that patients with
preexisting respiratory diseases have higher mortal-
ity. According to the global burden of disease, Chronic
Obstructive Pulmonary Disease (COPD) is the third
leading cause of death worldwide [9] and chronic lower
respiratory diseases have been identified as the fourth
leading cause of death in the US accounting for 5.7%
of total deaths [10]. Obstructive sleep apnea (OSA) is
another common preexisting respiratory condition
affecting close to 1 billion people worldwide, with high
prevalence in the US [11]. However limited informa-
tion is available describing mortality and the need for
mechanical ventilation in patients with preexisting res-
piratory diseases and COVID-19.

A study by the Chinese Center for Disease Control
and Prevention had reported an average case-fatality
rate of around 2.3%, however, significantly higher mor-
tality was noted in critically ill patients in intensive care
[4]. Other studies have reported that 2–3% of patients
infected with COVID-19 require mechanical ventila-
tion [12–14] and reported a case fatality rate of 1.2% in
the US [15].

is abundant on the negative impact of
smoking on lung health and its association with a
plethora of respiratory conditions. Smoking is also det-
rimental to the immune system [16] and its response to
various infections. Studies have delineated the implica-
tions of increased risk of infection among smokers [17].
Recently an association of smoking with negative pro-
gression and adverse outcomes in COVID-19 patients
has been reported [18].

The increased number of COVID-19 patients pre-
senting with critical illness has resulted in limited
availability of intensive care beds and strained hospi-
tal resources [19]. It is important to identify patients
who are at risk for critical illness, need intensive care
and mechanical ventilation to optimize the use of criti-
cal care resources, especially in inner-city and pre-
dominantly underserved areas. It can aid in efficient
resource allocation, planning for critical care surge, and
appropriate deployment of health care workers.

The main objective of this study is to determine the
correlation between preexisting respiratory diseases
and severe disease outcomes i.e. mortality, need for
mechanical ventilation, and intensive care unit (ICU)
admission among COVID-19 patients. Our study
also explores if the history of smoking in COVID-19
patients is associated with the severe disease outcomes
mentioned above.

Methods
Study design
We conducted a retrospective cohort study on 1871
adult patients with confirmed COVID-19 diagnosis. This
study was deemed exempt by the Detroit Medical Center
(DMC) and Wayne State University institutional review
board. (IRB application #20-07-2528). No external fund-
ing was received for conducting the study.

Study site and patient population
Adult patients (≥ 18  years of age) with a confirmed
COVID-19 diagnosis (either via nasopharyngeal or oro-
pharyngeal swab) were included. Testing for COVID-19
was done at the DMC, one of the largest academic medi-
cal centers and healthcare providers in Southeast Michi-
gan. DMC comprises four distinct hospitals in Michigan
and data from all four hospitals have been included in
this study. These hospitals primarily serve the Detroit
metropolitan area catering to an underserved population
majority of which is African American.

Data collection
A list of patients was collected in collaboration with insti-
tutional information technology services. Patients who
visited DMC between March 10, 2020, and June 30, 2020,
with a laboratory confirmed COVID-19 PCR diagnosis
were included. Patients under the age of 18, any readmis-
sion during the time frame, ambulatory surgery patients,
and pregnant patients were excluded from the study.
Patients who were transferred to an outside facility for
extracorporeal membrane oxygenation (ECMO) therapy
were also excluded.

To determine preexisting respiratory diseases and
smoking status, along with other variables, we manu-
ally searched through clinical notes, emergency depart-
ment (ED) notes, and prior history tab in the electronic
medical records (EMR). Preexisting respiratory diseases
included in the study were COPD, asthma, pulmonary
hypertension, OSA, pulmonary embolism, sarcoidosis,
lung cancer, prior tuberculosis, and interstitial lung dis-
ease. Data points were manually collected and coded for
each patient. Data regarding radiographic imaging dur-
ing hospitalization, initial chest X-ray and chest com-
puterized tomography (CT) scan were also collected for
all the patients, whenever available. The severity of the
preexisting respiratory diseases was also noted, if the
information was available. Disease severity for each con-
dition was determined as follows: (a) COPD severity was
based on the GOLD grade using the pulmonary function
tests (PFTs), (b) OSA severity was classified based on the
apnea–hypopnea index (AHI) from the sleep studies,
(c) asthma severity was determined based upon symp-
toms, nocturnal awakening and PFT’s (d) pulmonary

Page 3 of 9Lohia et al. Respir Res (2021) 22:37

hypertension, based on mean pulmonary arterial pres-
sure on right heart catheterization, and (e) sarcoido-
sis, based on the baseline chest X-ray findings. Positive
smoking status was established based on the documented
smoking history on the review of EMR. Quantification
of the amount of smoking and categorization of smokers
into current and former smokers could not be done due
to the lack of consistent documentation in EMR. Also,
the nature and clinical course of the patient’s hospitaliza-
tion and their disposition from the ED visit were noted.

Outcomes
The main outcomes for this study were mortality, need
for mechanical ventilation, and ICU admission. Together,
they have been referred to as severe disease outcomes in
COVID-19. All of the patients included in the study had
a documented acute care endpoint (mortality/discharged
status) at the time of data collection. Additionally, the
number and type of prior comorbidities, BMI, disposi-
tion upon ED visit (discharge home, inpatient admission,
and direct ICU admission) were collected. Data regard-
ing whether or not the patient received corticosteroid
treatment during the course of their hospitalization were
also obtained. Charts were screened to determine if the
patient required up-gradation of care to the ICU from
inpatient floors. Demographic data collected included
age, sex, and race.

Statistical analysis
Categorical variables have been described as frequency
and percentages, and continuous variables have been
described as mean and standard deviation. A crude rela-
tive association measure (Odds ratio, OR) was calculated
for each correlation using the Pearson chi-square and
Fisher test. An adjusted odds ratio was calculated using
binary logistic regression. In the fully adjusted models,
adjustments were made for age, sex, race, BMI, and prior
comorbidities including, hypertension, coronary artery
disease (CAD), congestive heart failure (CHF), diabe-
tes, any history of cancer and prior liver disease, chronic
kidney disease (CKD), end-stage renal disease (ESRD)
on dialysis, hyperlipidemia and history of prior stroke.
Age and BMI were taken as continuous variables while
the remaining were categorical variables. A p-value of
less than 0.05 was determined to be significant. Stepwise
regression using forward selection (Wald) method was
also performed to obtain an optimal model and further
validate the findings. Subgroup analyses were done based
on the type of preexisting respiratory disease. Analysis
based on the severity of preexisting respiratory disease
could not be conducted due to the non-availability of this
data for a large number of patients. Statistical analyses

were completed using IBM SPSS software (ver-
sion 26).

Results
Baseline characteristics
There were 2001 adult patient records with positive
COVID-19 test at the 4 DMC hospitals with a naso-
pharyngeal/oropharyngeal PCR swab between March 10,
2020, and June 30, 2020. A total of 130 patient records
were excluded based on the exclusion criteria, and 1871
patients were included in the study. In the cohort anal-
ysis, there was an almost equal distribution of males
(n = 965, 51.6%) and females (n = 906, 48.4%). The mean
age of patients was 64.11  years (Standard deviation SD
16). More than half the patients (n = 997, 53.3%) were
65  years or older, with African Americans being the
predominant race (n = 1494, 79.9%). About 43% of the
patients had three or more comorbid diseases (n = 809).
The mean BMI of the patient cohort was 31.14 kg/m2 (SD
8.82) and 47% (n = 897) patients were in the obese cat-
egory, 23 patients were missing BMI information in the
chart. About 30.7% of all the patients (n = 575) had a doc-
umented preexisting respiratory disease as part of their
medical history. Additionally, 37.6% (n = 704) of patients
had a history of smoking identified as a part of their
social history. The baseline characteristics of the popula-
tion included are detailed in Table 1.

Clinical course
The total mortality in the cohort was 32.8% (n = 613).
About 17.5% (n = 327) patients were admitted directly
to ICU from the ED. An additional 265 were later trans-
ferred to ICU from the inpatient service. Approximately
one in every three patients (31.6%) who presented to ED
ended up requiring ICU services. Around 8.8% of the
total patients were sent home from ED (n = 165), while
73.7% (n = 1379) were admitted to the inpatient ser-
vice. During the course of hospitalization, 26.1% of the
patients (n = 489) required mechanical ventilation. Uni-
lateral/bilateral infiltrates on chest X-ray at admission
was the most common radiographical finding. Further
details on the clinical course of the patients and radio-
graphical findings are summarized in Table 2.

Preexisting respiratory disease and severe disease
outcomes
Patients with preexisting respiratory diseases had signifi-
cantly higher mortality, higher need for ICU admission,
and a greater need for mechanical ventilation, compared
to the patients without preexisting respiratory diseases.
In unadjusted analysis, patients with preexisting res-
piratory disease were associated with higher mortality,
compared to those without any preexisting respiratory

Page 4 of 9Lohia et al. Respir Res (2021) 22:37

disease (OR = 1.29; 95% CI, 1.05–1.58; p = 0.02). Having
a preexisting respiratory disease was also associated with
a higher rate of ICU admission (OR, 1.33; 95% CI, 1.08–
1.64; p = 0.007) as well as increased need for mechanical
ventilation (OR, 1.40; 95% CI, 1.13–1.74; p = 0.002).

Even after adjusting for age, sex, race, BMI, and prior
comorbidities including, hypertension, CAD, CHF,

Table 1 Baseline characteristics of patients

Characteristics Cohort (n = 1871)

Age, n (%)
Mean (SD) 64.11 (16)

< 65 874 (46.7) ≥ 65 997 (53.3) Sex, n (%) Male 965 (51.6) Female 906 (48.4) Race/ethnicity, n (%) African American 1494 (79.9) White 340 (18.2) Asian 21 (1.1) Middle Eastern 14 (0.7) Latino/Hispanic 2 (0.1) BMI, mean (SD) 31.14 (8.82) < 18.5 (underweight) 46 (2.5) 18.5–24.9 (normal) 411 (22) 25–29.9 (overweight) 512 (27.4) ≥ 30 (obese) 897 (47) Preexisting respiratory disease, n (%) 575 (30.7) COPD 317 (16.9) Asthma 134 (7.2) Obstructive sleep apnea 63 (3.4) Pulmonary embolism 27 (1.4) Pulmonary hypertension 10 (0.5) Sarcoidosis 8 (0.4) Lung cancer 9 (0.5) Prior TB/ILD 5 (0.3) Number of comorbidities, n (%) 0 257 (13.7) 1 362 (19.3) 2 443 (23.7) ≥ 3 809 (43.2) Current or former smoker, n (%) 704 (37.6) Individual preexisting respiratory disease severity  COPD, n (%) 317 GOLD grade I 40 (12.6) GOLD grade II 18 (5.7) GOLD grade III 16 (5) GOLD grade IV 5 (1.6) Cannot be determined 238 (75.1) Asthma, n (%) 134 Intermittent 9 (6.7) Mild 13 (9.7) Moderate 5 (3.7) Severe 2 (1.5) Cannot be determined 105 (78.4) Obstructive sleep apnea, n (%) 63 Mild (5 ≤ AHI < 15) 7 (11.1) Moderate (15 ≤ AHI < 30) 6 (9.5) SD Standard deviation, AHI Apnea–hypopnea index, mPAP Mean pulmonary arterial pressure mPAP Mean pulmonary arterial pressure Table 1 (continued) Characteristics Cohort (n = 1871) Severe (AHI ≥ 30) 18 (28.6) Cannot be determined 32 (50.8) Pulmonary Hypertension (based on mPAP), n (%) 10 Mid 4 (40) Moderate 1 (10) Severe 2 (20) Cannot be determined 3 (30) Sarcoidosis, n (%) 8 Stage 0 3 (37.5) Stage 1 2 (25) Cannot be determined 3 (37.5) Table 2 Clinical course of patients (cohort n = 1871) Mortality 613 (32.8) Mechanical ventilation 489 (26.1) ICU admission 592 (31.6) Admission disposition ER Visit Only (Discharged from ER) 165 (8.8) Inpatient Admission 1379 (73.7) Direct ER to ICU admission 327 (17.5) Chest x-ray at admission 1821 Infiltrates (unilateral/bilateral) 1242 (68.2) Atelectasis 208 (11.4) Pleural effusion 31 (1.7) Pulmonary vascular congestion/edema 106 (5.8) Normal 234 (12.9) CT scan findings during admission 93 Consolidation 15 (16.1) Ground glass opacities 59 (63.4) Pulmonary infiltrates (unilateral/bilateral) 11 (11.8) Interstitial abnormalities (reticular, fibrous stripes, inter- lobular septal thickening) 7 (7.5) Normal 1 (1.1) Corticosteroids during admission 571 Preexisting respiratory disease 230 (40.3) No preexisting respiratory disease 341 (59.7) Page 5 of 9Lohia et al. Respir Res (2021) 22:37 diabetes, any history of cancer and prior liver disease, CKD, ESRD on dialysis, hyperlipidemia, and history of prior stroke, patients with preexisting respiratory diseases had higher mortality (adjusted(a)OR = 1.36; 95% CI, 1.08–1.72; p = 0.01), increased need for ICU admission (aOR = 1.34; 95% CI, 1.07–1.68; p = 0.009), and higher rates of requiring mechanical ventilation (aOR = 1.36; 95% CI, 1.07–1.72; p = 0.01). Further details on the results of unadjusted models and fully adjusted models for the association between preexisting respira- tory disease and the three severe disease outcomes are outlined in Table  3. The results for stepwise regression models exploring the association between preexisting respiratory disease and the clinical outcomes have been summarized in Table 4. Type of preexisting respiratory disease and severe disease outcomes Among patients with preexisting respiratory diseases, the most prevalent condition was COPD, present in more than half of the patients (n = 317). In the unadjusted models, COPD (OR, 1.47; 95% CI, 1.14–1.88; p = 0.002), Asthma (OR, 0.57; 95% CI, 0.38–0.87; p = 0.008) and OSA (OR, 2.04; 95% CI, 1.23–3.37; p = 0.005) dem- onstrated significant association with mortality. The need for mechanical ventilation was also significantly higher for patients with COPD (OR, 1.35; 95% CI, 1.04– 1.76; p = 0.02) and OSA (OR, 2.85; 95% CI, 1.72–4.73; p < 0.001). In fully adjusted models, however, only the association of OSA with the three severe disease out- comes was found to be statistically significant, mortality (aOR, 2.59; 95% CI, 1.46–4.58; p = 0.001), ICU admis- sion (aOR, 1.95; 95% CI, 1.14–3.32; p = 0.01) and need for mechanical ventilation (aOR, 2.20; 95% CI, 1.28–3.78; p = 0.004). Table  5 summarizes the association of dif- ferent preexisting respiratory diseases with the severe disease outcomes in the unadjusted as well as the fully adjusted models. Smoking and severe disease outcomes Smoking was associated with higher mortality (OR, 1.26; 95% CI, 1.03–1.53; p = 0.02) and increased need for ICU admission (OR, 1.33; 95% CI, 1.09–1.62; p = 0.005). The association between smoking and the need for Table 3 Association between  preexisting respiratory disease/smoking and  severe disease outcomes- Mortality, Mechanical ventilation and ICU admission unadjusted and adjusted for age, sex, race, BMI and comorbidities *Fully adjusted for age, sex, race, BMI and comorbidities which include hypertension, coronary artery disease, diabetes, chronic kidney disease, ESRD on dialysis, congestive heart failure, any cancer, any liver disease, hyperlipidemia and history of previous stroke OR odds ratio, CI Confidence Interval Characteristic Mortality ICU Admission Mechanical ventilation OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value Preexisting respiratory disease Unadjusted 1.29 (1.05–1.58) 0.02 1.33 (1.08–1.64) 0.007 1.40 (1.13–1.74) 0.002 Fully adjusted* 1.36 (1.08–1.72) 0.01 1.34 (1.07–1.68) 0.009 1.36 (1.07–1.72) 0.01 Smoking Unadjusted 1.26 (1.03–1.53) 0.02 1.33 (1.09–1.62) 0.005 1.23 (0.99–1.52) 0.05 Fully adjusted* 1.14 (0.91–1.42) 0.25 1.25 (1.01–1.55) 0.03 1.15 (0.92–1.44) 0.21 Table 4 Association between  preexisting respiratory disease/smoking and  severe disease outcomes- Mortality, Mechanical ventilation and ICU admission (using stepwise regression, forward selection Wald approach) *Variables in the optimal model- age, sex, BMI, diabetes, chronic kidney disease and preexisting respiratory diseases **Variables in the optimal model- age, sex, BMI, diabetes, chronic kidney disease and preexisting respiratory diseases ***Variables in the optimal model- age, sex, BMI, diabetes, hypertension, and preexisting respiratory diseases ^Variables in the optimal model- age, sex, BMI, diabetes, chronic kidney disease and smoking OR odds ratio, CI confidence interval, NS nonsignificant Mortality ICU Admission Mechanical ventilation OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value Preexisting respiratory diseases 1.38 (1.10–1.74)* 0.005 1.34 (1.08–1.66)** 0.009 1.34 (1.07–1.69)*** 0.01 Smoking NS 1.28(1.04–1.57)^ 0.02 NS Page 6 of 9Lohia et al. Respir Res (2021) 22:37 mechanical ventilation was not statistically significant (OR, 1.23; 95% CI, 0.99–1.52; p = 0.05). After adjusting for age, sex, race, BMI, and comorbidities, a significant association was only noted between smoking and ICU requirement (aOR, 1.25; 95% CI, 1.01–1.55; p = 0.03). Table  3 outlines the association of smoking with severe disease outcomes. Discussion This retrospective cohort study provides novel findings indicating the role of preexisting respiratory diseases as an important predictor of severe disease outcomes in patients hospitalized with COVID-19. The study dem- onstrated a significant association between the pres- ence of preexisting respiratory diseases and mortality, ICU admission, and need for mechanical ventilation. Even when adjusted for possible confounders such as age, sex, race, BMI and ten prevalent comorbidities, patients with preexisting respiratory disease had sig- nificantly higher mortality, greater need for ICU admis- sion, and increased need for mechanical ventilation. Hence, the study demonstrates that preexisting respira- tory diseases are an important predictor for severe dis- ease outcomes in COVID 19 patients. Hypertension, coronary artery disease, and diabetes are the most common reported comorbidities among COVID-19 patients [6, 20–24], and they have been found to be associated with severe disease outcomes. Studies from China [5, 12, 13, 25–27] and Italy [28] have reported that patients with chronic lung diseases have worse clinical outcomes, however, they evaluated a much smaller cohort. Obesity also has been reported by some, to be a risk factor for mortality in COVID-19 [20, 29, 30]. To date, the literature on the role of pre- existing respiratory conditions in the clinical course of COVID-19 positive patients has been limited, and our study highlights that the presence of preexisting Table 5 Association between  individual preexisting respiratory disease and  severe disease outcomes- Mortality, Mechanical ventilation and ICU admission *Fully adjusted for age, sex, race, BMI and comorbidities which include hypertension, coronary artery disease, diabetes, chronic kidney disease, ESRD on dialysis, congestive heart failure, any cancer, any liver disease, hyperlipidemia and history of previous stroke OR odds ratio, CI Confidence Interval Characteristic Number of events n (%) Unadjusted Fully adjusted* OR (95% CI) p-value OR (95% CI) p-value Mortality COPD 127 (40.1) 1.47 (1.14–1.88) 0.002 1.20 (0.91–1.58) 0.2 Asthma 30 (22.4) 0.57 (0.38–0.87) 0.008 0.98 (0.61–1.58) 0.94 Obstructive sleep apnea 31 (49.2) 2.04 (1.23–3.37) 0.005 2.59 (1.46–4.58) 0.001 Pulmonary embolism 13 (48.1) 1.92 (0.90–4.12) 0.09 1.86 (0.82–4.23) 0.14 Pulmonary hypertension 4 (40) 1.37 (0.38–4.87) 0.62 1.09 (0.28–4.23) 0.9 Sarcoidosis 1 (12.5) 0.29 (0.04–2.38) 0.28 0.39 (0.04–3.46) 0.4 Lung cancer 4 (44.4) 1.65 (0.44–6.15) 0.45 1.24 (0.30–5.10) 0.76 ICU admission COPD 114 (36) 1.26 (0.98–1.63) 0.07 1.20 (0.92–1.58) 0.18 Asthma 41 (30.6) 0.95 (0.65–1.39) 0.79 1.16 (0.77–1.74) 0.47 Obstructive sleep apnea 32 (50.8) 2.3 (1.39–3.80) 0.001 1.95 (1.14–3.32) 0.01 Pulmonary embolism 13 (48.1) 2.30 (0.95–4.34) 0.06 2.03 (0.93–4.44) 0.08 Pulmonary hypertension 4 (40) 1.44 (0.41–5.13) 0.57 1.25 (0.34–4.62) 0.74 Sarcoidosis 1 (12.5) 0.31 (0.04–2.50) 0.49 0.39 (0.05–3.21) 0.38 Lung cancer 2 (22.2) 0.62 (0.13–2.97) 0.54 0.63 (0.12–3.28) 0.58 Mechanical ventilation COPD 99 (31.2) 1.35 (1.04–1.76) 0.02 1.28 (0.96–1.69) 0.09 Asthma 33 (24.6) 0.92 (0.61–1.38) 0.68 1.08 (0.69–1.67) 0.74 Obstructive sleep apnea 31 (49.2) 2.85 (1.72–4.73) < 0.001 2.20 (1.28–3.78) 0.004 Pulmonary embolism 9 (33.3) 1.42 (0.63–3.18) 0.39 1.45(0.63–3.34) 0.39 Pulmonary hypertension 3 (30) 1.21 (0.31–4.70) 0.72 0.96 (0.23–3.92) 0.95 Sarcoidosis 1 (12.5) 0.40 (0.0–3.28) 0.69 0.52 (0.06–4.30) 0.54 Lung cancer 1 (11.1) 0.35 (0.04–2.82) 0.46 0.35 (0.04–3.00) 0.34 Page 7 of 9Lohia et al. Respir Res (2021) 22:37 respiratory diseases has a significant impact on clinical outcomes. To our knowledge, this is the first study that has looked at the association of all the prominent respira- tory diseases with severe disease outcomes in COVID- 19 patients. Patients with OSA had significantly higher mortality, a higher need for mechanical ventilation, and a greater need for ICU admission in our study. A recent study by Cade et  al. [31] also noted a significant crude association between sleep apnea and mortality. However, in their study, the associations were somewhat attenuated after adjusting for BMI and other comorbidities. Another study by Maas et  al. [32] reported that OSA was associ- ated with an increased risk of hospitalization and approx- imately double the risk of developing respiratory failure. The patients with OSA in our study were also more than twice as likely to require mechanical ventilation, com- pared to the patients without OSA. Prior diagnosis of OSA in COVID-19 patients has also been reported to be associated with increased risk of death at day 7 [33]. A review by Miller et  al. [34] provides a plausible explana- tion linking OSA and COVID-19. It hypothesizes that periods of hypercapnia and hypoxemia, surges of sympa- thetic activation, and increased inflammatory markers in OSA, may contribute to worse outcomes in COVID-19 patients. Further research is warranted to better under- stand the mechanism by which OSA might be contribut- ing to worse clinical outcomes in COVID-19 patients. In our study, patients with COPD also had increased mortality and a higher need for mechanical ventilation. However, upon adjusting for age, sex, race, BMI, and comorbidities, associations were attenuated and failed to reach the level of traditional significance. In the study by Grasselli et  al. [28] COPD was noted to be significantly associated with mortality in multivariable analysis, how- ever, this study did not adjust for BMI which could be a possible confounder and was accounted for in our study. Also, in their cohort of 3988 ICU patients, only 0.02% …